Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-PROPAFENONE | 150MG | TABLET | Resolved | 2023-04-27 | 2023-07-07 | 190856 |
| APO-PROPAFENONE | 300MG | TABLET TABLET | Resolved | 2023-05-06 | 2023-07-07 | 191871 |
| APO-PROPAFENONE | 150MG | TABLET | Resolved | 2017-09-27 | 2018-08-30 | 23632 |
| APO-PROPAFENONE | 150MG | TABLET | Resolved | 2022-02-11 | 2022-03-25 | 154765 |
| APO-PROPAFENONE | 150MG | TABLET | Resolved | 2024-03-22 | 2024-04-26 | 223049 |
| APO-PROPAFENONE | 150MG | TABLET | Resolved | 2020-09-17 | 2020-10-05 | 124356 |
| APO-PROPAFENONE | 150MG | TABLET | Resolved | 2021-04-23 | 2021-05-31 | 137968 |
| APO-PRUCALOPRIDE | 1MG | TABLET | Resolved | 2023-10-06 | 2023-12-01 | 206557 |
| APO-PRUCALOPRIDE | 2MG | TABLET | Resolved | 2023-11-10 | 2023-12-01 | 209922 |
| APO-PRUCALOPRIDE | 1MG | TABLET | Resolved | 2024-07-25 | 2024-08-09 | 233700 |
| APO-PRUCALOPRIDE | 2MG | TABLET | Resolved | 2020-09-22 | 2020-11-27 | 124795 |
| APO-PRUCALOPRIDE | 1MG | TABLET | Resolved | 2021-03-19 | 2021-04-19 | 136044 |
| APO-PRUCALOPRIDE | 1MG | TABLET | Resolved | 2022-07-15 | 2022-12-16 | 164749 |
| APO-PRUCALOPRIDE | 2MG | TABLET | Resolved | 2022-08-26 | 2022-12-16 | 168047 |
| APO-PRUCALOPRIDE | 1MG | TABLET | Resolved | 2024-02-16 | 2024-03-29 | 219834 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2017-05-02 | 2017-06-27 | 8702 |
| APO-QUETIAPINE | 200MG | TABLET | Resolved | 2017-05-04 | 2017-07-04 | 8883 |
| APO-QUETIAPINE | 300MG | TABLET | Resolved | 2018-07-31 | 2018-09-28 | 56989 |
| APO-QUETIAPINE | 25MG | TABLET | Resolved | 2021-04-30 | 2021-05-31 | 138352 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2021-05-14 | 2021-05-31 | 139416 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |